Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) just unveiled an update.
Shanghai Fosun Pharmaceutical has received approval from the National Association of Financial Market Institutional Investors for the registration of RMB4 billion in medium term notes and RMB6 billion in super short-term commercial papers. These financial instruments will be issued in tranches over a two-year period starting March 2025, with Bank of Shanghai and China Merchants Bank as joint lead underwriters. This strategic move is expected to enhance the company’s financial flexibility and support its capital needs, potentially strengthening its market position.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of pharmaceutical products, medical devices, and healthcare services.
YTD Price Performance: 7.95%
Average Trading Volume: 5,063
Technical Sentiment Signal: Hold
Current Market Cap: $8.24B
See more insights into 2196 stock on TipRanks’ Stock Analysis page.